NCT02016365View on ClinicalTrials.gov

Safety and Efficacy Study of Doxycycline/UrsoDeoxyCholicAcid on Disease Progression in ATTR Amyloidosis

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions

Transthyretin AmyloidosisCardiomyopathy

Interventions

DRUG

Doxycycline

200 mg/day (100 mg twice daily, orally) for 4 weeks with a pause of 2 weeks in combination with UDCA

DRUG

Ursodeoxycholic acid

750 mg/day (500 mg +250mg orally) continuously

Trial Locations (3)

SE-941 28

Dept of Clinical Medicin, Ptieå Hospital, Piteå

SE-931 86

Dept of clinical medicin, Skellefteå Hospital, Skellefteå

SE-90185

Dept of Clinical Medicine, Umeå University Hospital, Umeå

All Listed Sponsors

lead

Umeå University

OTHER

NCT02016365 - Safety and Efficacy Study of Doxycycline/UrsoDeoxyCholicAcid on Disease Progression in ATTR Amyloidosis | Biotech Hunter | Biotech Hunter